Hester A. de Groot‐Kruseman

2.0k citations

43 papers · 988 indexed · h-index 16

Hematology top 2%
- Chronic Myeloid Leukemia Treatments 12
- Acute Myeloid Leukemia Research 8
Public Health, Environmental and Occupational Health top 2%
- Acute Lymphoblastic Leukemia research 28
Pediatrics, Perinatology and Child Health top 2%
- Childhood Cancer Survivors' Quality of Life 15
Orthopedics and Sports Medicine top 5%
- Bone and Joint Diseases 4
Speech and Hearing top 10%
- Adolescent and Pediatric Healthcare 4
Surgery
- Transplantation: Methods and Outcomes 7
Oncology
- Bone health and treatments 3

Co-authors: Rob Pieters Inge M. van der Sluis Monique L. den Boer Gabriele Escherich Martin A. Horstmann Wim C.J. Hop Judith M. Boer Aurélie Boeree
Cited by: Hematology Public Health, Environmental and Occupational Health Pediatrics, Perinatology and Child Health
Journals: Journal of Clinical Oncology (3 papers)Blood (11 papers)Scientific Reports (2 papers)
Partner nations: Netherlands Germany United States

In The Last Decade

Hester A. de Groot‐Kruseman

40 papers receiving 979 citations

Peers

Countries citing papers authored by Hester A. de Groot‐Kruseman

Since Specialization

Citations

This map shows the geographic impact of Hester A. de Groot‐Kruseman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hester A. de Groot‐Kruseman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hester A. de Groot‐Kruseman more than expected).

Fields of papers citing papers by Hester A. de Groot‐Kruseman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hester A. de Groot‐Kruseman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hester A. de Groot‐Kruseman. The network helps show where Hester A. de Groot‐Kruseman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Hester A. de Groot‐Kruseman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hester A. de Groot‐Kruseman Line = papers co-authored together Hester A. de Groot‐Kruseman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia? Leukemia ·Janine Stutterheim,Rachella van der Waarden,Hester A. de Groot‐Kruseman,Edwin Sonneveld,Válerie de Haas,Rana Dandis,C. Ellen van der Schoot,Vincent H. J. van der Velden,Rob Pieters	2024	2
2	Tyrosine kinase inhibitor resistance in de novo BCR::ABL1–positive BCP-ALL beyond kinase domain mutations Blood Advances ·Inge van Outersterp,Judith M. Boer,Cesca van de Ven,Caitlin E. J. Reichert,Aurélie Boeree,Brian Kruisinga,Hester A. de Groot‐Kruseman,Gabriele Escherich,Anikó Sijs‐Szabó,Anita W. Rijneveld,Monique L. den Boer	2024	1
3	Novel Insights in TKI Resistance in BCR:: ABL1-Positive B-Cell Acute Lymphoblastic Leukemia Beyond Kinase Domain Mutations Blood ·Inge Van Outersterp,Caitlin E. J. Reichert,Aurélie Boeree,Cesca van de Ven,Brian Kruisinga,Hester A. de Groot‐Kruseman,Gabriele Escherich,Anita W. Rijneveld,Judith M. Boer,Monique L. den Boer	2023	1
4	Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms Cancer Discovery ·Eline J.M. Bertrums,Axel Rosendahl Huber,Jurrian K. de Kanter,Arianne M. Brandsma,Anaïs J.C.N. van Leeuwen,Mark Verheul,Marry M. van den Heuvel‐Eibrink,Rurika Oka,Markus J. van Roosmalen,Hester A. de Groot‐Kruseman,C. Michel Zwaan,Bianca F. Goemans,Ruben van Boxtel	2022	16
5	Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study The Lancet Haematology ·Naomi Michels,Judith M. Boer,Amir Enshaei,Rosemary Sutton,Mats Heyman,Sabine Ebert,Marta Fiocco,Hester A. de Groot‐Kruseman,Vincent H. J. van der Velden,Gisela Barbany,Gabriele Escherich,Ajay Vora,Toby N. Trahair,Luciano Dalla‐Pozza,Rob Pieters,Udo zur Stadt,Kjeld Schmiegelow,Anthony V. Moorman,C. Michel Zwaan,Monique L. den Boer	2021	10
6	Effect of post-consolidation regimen on symptomatic osteonecrosis in three DCOG acute lymphoblastic leukemia protocols Haematologica ·Jenneke E. van Atteveld,Hester A. de Groot‐Kruseman,Marta Fiocco,Maarten H. Lequin,Sebastian Neggers,Saskia M.F. Pluijm,Inge M. van der Sluis,Rob Pieters,Marry M. van den Heuvel‐Eibrink	2020	7
7	Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia Scientific Reports ·Elisabeth M. P. Steeghs,Judith M. Boer,Alex Q. Hoogkamer,Aurélie Boeree,Válerie de Haas,Hester A. de Groot‐Kruseman,Martin A. Horstmann,Gabriele Escherich,Rob Pieters,Monique L. den Boer	2019	34
8	Venous thromboembolism in a large cohort of children with acute lymphoblastic leukemia: Risk factors and effect on prognosis Research and Practice in Thrombosis and Haemostasis ·Irene L M Klaassen,Mandy N. Lauw,Marta Fiocco,Inge M. van der Sluis,Rob Pieters,Saskia Middeldorp,Marianne D. van de Wetering,Hester A. de Groot‐Kruseman,C. Heleen van Ommen	2019	38
9	High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia Scientific Reports ·Elisabeth M. P. Steeghs,Marjolein Bakker,Alex Q. Hoogkamer,Judith M. Boer,Quirine J. Hartman,Femke Stalpers,Gabriele Escherich,Válerie de Haas,Hester A. de Groot‐Kruseman,Rob Pieters,Monique L. den Boer	2018	11
10	Risk-adapted approach for fever and neutropenia in paediatric cancer patients – A national multicentre study European Journal of Cancer ·Karin G. E. Miedema,Wim J. E. Tissing,Floor Abbink,Lynne M. Ball,Erna Michiels,Michel J. van Vliet,Wilma Y. de Vries,Willem A. Kamps,Obbe F. Norbruis,Marta Fiocco,Hester A. de Groot‐Kruseman,Marianne D. van de Wetering,Eveline S.J.M. de Bont	2015	39
11	Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemia Haematologica ·Marissa A. H. den Hoed,Saskia M.F. Pluijm,M.L. te Winkel,Hester A. de Groot‐Kruseman,Marta Fiocco,Peter M. Hoogerbrugge,J. A. Leeuw,Marrie C.A. Bruin,Inge M. van der Sluis,Dorine Bresters,Maarten H. Lequin,Jan C. Roos,A. Veerman,Rob Pieters,Marry M. van den Heuvel‐Eibrink	2015	20
12	The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia Haematologica ·Marissa A. H. den Hoed,Saskia M.F. Pluijm,Hester A. de Groot‐Kruseman,M.L. te Winkel,M. Fiocco,Erica L T van den Akker,P.M. Hoogerbrugge,Henk van den Berg,J. A. Leeuw,Marrie C.A. Bruin,Dorine Bresters,A. Veerman,Rob Pieters,Marry M. van den Heuvel‐Eibrink	2014	38
13	Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL Blood ·Arian van der Veer,Esmé Waanders,Rob Pieters,Marieke E. Willemse,Simon V. van Reijmersdal,Lisa J. Russell,Christine J. Harrison,William E. Evans,Vincent H. J. van der Velden,Peter M. Hoogerbrugge,Frank N. van Leeuwen,Gabriele Escherich,Martin A. Horstmann,Leila mohammadi Khankahdani,Dimitris Rizopoulos,Hester A. de Groot‐Kruseman,Edwin Sonneveld,Roland P. Kuiper,Monique L. den Boer	2013	187
14	Outcome after first relapse in children with acute lymphoblastic leukemia: A report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol Pediatric Blood & Cancer ·Henk van den Berg,Hester A. de Groot‐Kruseman,Carin M. Damen‐Korbijn,E. S. J. M. de Bont,Antoinette Y. N. Schouten‐van Meeteren,Peter M. Hoogerbrugge	2011	26
15	Apoptotic death of infiltrating cells in human cardiac allografts is regulated by IL-2, FASL, and FLIP Transplantation Proceedings ·Hester A. de Groot‐Kruseman,Carla C. Baan,Pieter E. Zondervan,Roel A. de Weger,Hubert G.M. Niesters,Aggie H.M.M. Balk,W. Weimar	2004	8
16	Intragraft interleukin 2 mRNA expression during acute cellular rejection and left ventricular total wall thickness after heart transplantation Heart ·Hester A. de Groot‐Kruseman,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2002	12
17	Sequential monitoring of intragraft cytokine mRNA expression in relation to diastolic left ventricular wall thickness and function early after heart transplantation Clinical Transplantation ·Hester A. de Groot‐Kruseman,Carla C. Baan,Elly M. Hagman,Wendy M. Mol,Hubert G.M. Niesters,Alex P.W.M. Maat,Pascal Vantrimpont,Pieter E. Zondervan,Willem Weimar,Aggie H.M.M. Balk	2002	5
18	Failure to down-regulate intragraft cytokine mRNA expression shortly after clinical heart transplantation is associated with high incidence of acute rejection The Journal of Heart and Lung Transplantation ·Hester A. de Groot‐Kruseman,Carla C. Baan,E. H. M. Loonen,Wendy M. Mol,Hubert G.M. Niesters,Alex P.W.M. Maat,Aggie H.M.M. Balk,Willem Weimar	2001	11
19	Intragraft platelet-derived growth factor-α and transforming growth factor-β1 during the development of accelerated graft vascular disease after clinical heart transplantation Transplant Immunology ·Hester A. de Groot‐Kruseman,Carla C. Baan,Wendy M. Mol,Hubert G.M. Niesters,Alex P.W.M. Maat,Aggie H.M.M. Balk,W. Weimar	1999	6
20	Upregulated transforming growth factor-β1 mRNA expression in endomyocardial biopsies during the development of graft vascular disease after clinical heart transplantation Transplantation Proceedings ·Hester A. de Groot‐Kruseman,Carla C. Baan,Wendy M. Mol,Hubert G.M. Niesters,Alex P.W.M. Maat,Aggie H.M.M. Balk,W. Weimar	1999	5

About Hester A. de Groot‐Kruseman

Hester A. de Groot‐Kruseman is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Pediatrics, Perinatology and Child Health, having authored 43 papers that have together received 988 indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (28 papers), Childhood Cancer Survivors' Quality of Life (15 papers), Chronic Myeloid Leukemia Treatments (12 papers), Acute Myeloid Leukemia Research (8 papers), Transplantation: Methods and Outcomes (7 papers), Adolescent and Pediatric Healthcare (4 papers), Bone and Joint Diseases (4 papers) and Bone health and treatments (3 papers). The work is most often cited by research in Hematology (457 citations), Public Health, Environmental and Occupational Health (662 citations) and Pediatrics, Perinatology and Child Health (402 citations). Hester A. de Groot‐Kruseman has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include Rob Pieters, Inge M. van der Sluis, Monique L. den Boer, Gabriele Escherich, Martin A. Horstmann, Wim C.J. Hop, Judith M. Boer, Aurélie Boeree, Marry M. van den Heuvel‐Eibrink and Elisabeth M. P. Steeghs. Their work appears in journals such as Journal of Clinical Oncology, Blood and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact